Hikma Pharmaceuticals PLC HIK.L
Hikma Pharmaceuticals PLC statistics & valuation
Multiples are price-derived and refreshed daily; everything else from the latest financial reports. The Graham number is Benjamin Graham's rough maximum fair value ($22.54); a green figure means the price is below it.
Profitability & efficiency
Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).
P / E vs its own history
Hikma Pharmaceuticals PLC trades at about 907.7× earnings — below its 10-year norm (10-year range 844.8×–2272.4×, median 2043.7×).
Shaded band = 10-year range (844.8×–2272.4×); dot = today's 907.7×.
Historical P/E = month-end price near each fiscal year-end ÷ that year's EPS. A read on whether the stock is cheap or dear relative to how it has typically been valued — not a forecast.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Gross margin | 43.0% | 45.3% | 48.3% | 49.2% |
| Operating margin | 18.9% | 19.6% | 21.2% | 19.1% |
| Net margin | 12.0% | 11.5% | 6.6% | 7.5% |
| FCF margin | 3.6% | 10.5% | 14.1% | 14.3% |
| Return on assets | 7.1% | 7.0% | 4.1% | 4.2% |
| Return on equity | 15.5% | 15.5% | 8.6% | 8.8% |
| Debt / equity | 0.56× | 0.26× | 0.44× | 0.50× |
| Current ratio | 1.82 | 1.14 | 1.57 | 1.86 |
Computed from company filings · GB · as of 2025-12-31. Figures in USD. Facts plus Stocktoria's own computed scores — not investment advice.